Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026

China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026

Matwings Technology, a pioneer in AI‑driven protein engineering, announced a strategic biopharmaceutical pipeline collaboration with...

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026

Tianjin AmCellGene Co., Ltd. has granted Hong Kong‑based Advanced Regeneration exclusive regional rights to commercialize...

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026

Huadong Medicine Co., Ltd. (SHE: 000963), a leading China‑based pharmaceutical group, announced an exclusive commercialization...

Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Fineline Cube Jan 22, 2026

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) announced that China’s National Medical Products Administration...

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Fineline Cube Jan 22, 2026

Abbott (NYSE: ABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo...

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...

Company R&D

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Fineline Cube Jan 22, 2026

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37, a next‑generation once‑monthly subcutaneous GLP‑1R/GIPR/GCGR triple‑agonist...

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026

Novavax, Inc. (NASDAQ: NVAX) entered into a license agreement with Pfizer Inc. for non‑exclusive rights to...

Company Drug

Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study

Fineline Cube Jan 22, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026

Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong...

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026

Bristol‑Myers Squibb (BMS, NYSE: BMY) announced a collaboration with Microsoft to accelerate early detection of non‑small...

Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026

Bayer AG (ETR: BAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five‑year collaboration to...

Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026

Hangzhou Diagens Biotechnology Co., Ltd. announced a filing for an initial public offering (IPO) to...

Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Fineline Cube Jan 22, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT) for USD 58.00...

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026

Alteogen Inc. (KOSDAQ: 196170) announced an exclusive license agreement with Tesaro, a GSK subsidiary, granting worldwide...

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...

Posts pagination

1 … 4 5 6 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.